We’re still in the early days of testing COVID-19 treatments. Even as health professionals provide supportive care, treating symptoms as the disease runs its course, UC Davis researchers are investigating the therapeutic possibilities.
In March 2020, UC Davis launched two clinical studies to evaluate the safety and effectiveness of two drugs — the antiviral remdesivir, and sarilumab, which blocks the body’s acute inflammatory response.
UC Davis Health was among the first to evaluate transfusions of plasma taken from patients who have recovered from COVID-19. The approach has been effective for treating infectious diseases such as measles, mumps, and hepatitis A as well as other coronavirus illnesses including SARS-1 and Middle East Respiratory Syndrome.
For now, the world waits impatiently for the ultimate prize — a vaccine that inoculates against the novel coronavirus. In early May, the UC Davis Mouse Biology Program began preclinical testing of a single-dose vaccination kit that uses a dermal patch with a metal microneedle array.
Until the pandemic is well under control, UC Davis will continue its search for effective, scalable solutions.